DDrare: Database of Drug Development for Rare Diseases

162. 類天疱瘡（後天性表皮水疱症を含む。）
［臨床試験数：70，薬物数：117（DrugBank：46），標的遺伝子数：30，標的パスウェイ数：128］

Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE; AC-203 1% Topical Ointment; AKST4290; ARAVA; Acetate; Apremilast; Avdoralimab; Avdoralimab (IPH5401); Azathioprine; Azathioprine or Mycophenolate mofetil; BIV009; Benralizumab; Bertilimumab; Blood test; CC; CC-10004; CORTANCYL 20 mg; Carboxymethylcellulose; Cellcept® in autoimmune bullous dermatoses; Cellulose; Clobetasol; Clobetasol 0.05% Topical Ointment; Clobetasol Propionate cream treatment; Clobetasol propionate; Clobetasol propionate + Methotrexate; Clobetasol propionate alone; Collagenase; Cortancyl; Cotton; Cultivated oral mucosal epithelial sheet transplantation; Cyclophosphamide; Cyclophosphamide 50Mg Oral Tablet; Cyclosporine; DERMOVAL; DF2156A; DUPILUMAB; Data report; Dermoval; Device: Carboxymethylcellulose with ionic silver (Aquacel Ag); Device: Cellulose acetate with petrolatum; Device: Cotton gauze with petrolatum; Device: Nanocrystalline silver (Acticoat); Dexamethasone; Dexamethasone 0.5mg/5ml solution; Dexamethasone 0.5mg/5ml solution in Mucolox™; Doxycycline; Dupilumab; Dupixent; Gold; Halometasone; INTERLEUKIN-2; IPH5401; Imatinib; Infliximab; Ixekizumab; Ladarixin; Leflunomide; MABTHERA; MTX; MabThera; Mabthera; Mabthéra; Mathéra; Medrone; Mepolizumab; Mepolizumab (a-IL-5 antibody); Methotrexate; Methylprednisolone; Minocycline; Mometasone; Mometasone furoate; Mycophenolate; Mycophenolate mofetil; Myfortic; Myfortic 180 mg; Myfortic 180 mg Filmtabletten; NNC0215-0384; NPB-01; Nicotinamide; Omalizumab; Oral corticosteroids (OCS); Otezla; Other: Blood sample and cotton skin swabs; Other: Control; PREDNISONE; Petrolatum; Prednisolone; Prednisone; Procedure: Clobetasol propionate; Procedure: Impedance analysis; Procedure: bone densitometry; Procedure: collagenase; Procedure: radiographs of the thoracic and lumbar spine; QGE031; RESTASIS; RITUXIMAB; RVA576; Riboflavin; Rituximab; Rituximab 1g IV; Rituximab combined with Omalizumab; SIMVASTATIN; Silver; Simvastatin; Simvastatin-ratiopharm; Simvastatin-ratiopharm®; Solu-Medrone; Tildrakizumab; Tildrakizumab Prefilled Syringe; Topical infliximab; Treatment systemic therapy (prednisone); Treatment with systemic therapy (doxycycline); Treatment with systemic therapy (methotrexate); Treatment with systemic therapy (prednisone); Treatment with topical superpotent corticosteroid therapy; Tripterygium; Ustekinumab

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03926377 (ClinicalTrials.gov)	April 2019	15/4/2019	Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid	Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid	Osteoporosis;Bullous Pemphigoid	Procedure: bone densitometry;Biological: blood test;Procedure: radiographs of the thoracic and lumbar spine;Procedure: Clobetasol propionate	Centre Hospitalier Universitaire, Amiens	University Hospital, Rouen	Not yet recruiting	18 Years	N/A	All	50	Phase 4	NULL
2	NCT03286582 (ClinicalTrials.gov)	September 5, 2017	14/9/2017	A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid	A Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous Pemphigoid	Bullous Pemphigoid	Drug: AC-203 1% Topical Ointment;Drug: Clobetasol 0.05% Topical Ointment	TWi Biotechnology, Inc.	NULL	Terminated	20 Years	90 Years	All	10	Phase 2	Taiwan
3	NCT02360202 (ClinicalTrials.gov)	April 2015	7/1/2015	Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid	Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid	Bullous Pemphigoid	Procedure: Impedance analysis;Drug: Clobetasol Propionate cream treatment	University Hospital, Rouen	Société de Dermatologie Française	Recruiting	18 Years	N/A	All	35	Phase 4	France
4	NCT02313870 (ClinicalTrials.gov)	January 2008	8/12/2014	Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid	Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid	Bullous Pemphigoid	Drug: clobetasol propionate + Methotrexate;Drug: clobetasol propionate alone	University Hospital, Montpellier	NULL	Recruiting	18 Years	N/A	Both	300	Phase 3	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03926377
(ClinicalTrials.gov)

April 2019

15/4/2019

Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid

Osteoporosis;Bullous Pemphigoid

Procedure: bone densitometry;Biological: blood test;Procedure: radiographs of the thoracic and lumbar spine;Procedure: Clobetasol propionate

Centre Hospitalier Universitaire, Amiens

University Hospital, Rouen

Not yet recruiting

18 Years

N/A

All

Phase 4

NULL

NCT03286582
(ClinicalTrials.gov)

September 5, 2017

14/9/2017

A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid

A Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous Pemphigoid

Bullous Pemphigoid

Drug: AC-203 1% Topical Ointment;Drug: Clobetasol 0.05% Topical Ointment

TWi Biotechnology, Inc.

NULL

Terminated

20 Years

90 Years

All

Phase 2

Taiwan

NCT02360202
(ClinicalTrials.gov)

April 2015

7/1/2015

Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid

Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid

Bullous Pemphigoid

Procedure: Impedance analysis;Drug: Clobetasol Propionate cream treatment

University Hospital, Rouen

Société de Dermatologie Française

Recruiting

18 Years

N/A

All

Phase 4

France

NCT02313870
(ClinicalTrials.gov)

January 2008

8/12/2014

Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid

Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid

Bullous Pemphigoid

Drug: clobetasol propionate + Methotrexate;Drug: clobetasol propionate alone

University Hospital, Montpellier

NULL

Recruiting

18 Years

N/A

Both

300

Phase 3

France